TW200637546A - Combination therapy - Google Patents

Combination therapy

Info

Publication number
TW200637546A
TW200637546A TW094144909A TW94144909A TW200637546A TW 200637546 A TW200637546 A TW 200637546A TW 094144909 A TW094144909 A TW 094144909A TW 94144909 A TW94144909 A TW 94144909A TW 200637546 A TW200637546 A TW 200637546A
Authority
TW
Taiwan
Prior art keywords
hydrochlorothiazide
combination therapy
telmisartan
angiotensin
treatment
Prior art date
Application number
TW094144909A
Other languages
English (en)
Chinese (zh)
Inventor
Helmut E Schumacher
Axel Riedel
Peter Boehm
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200637546(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200637546A publication Critical patent/TW200637546A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
TW094144909A 2004-12-17 2005-12-16 Combination therapy TW200637546A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
TW200637546A true TW200637546A (en) 2006-11-01

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094144909A TW200637546A (en) 2004-12-17 2005-12-16 Combination therapy

Country Status (15)

Country Link
EP (1) EP1827424A1 (enExample)
JP (1) JP2008524136A (enExample)
KR (1) KR20070097511A (enExample)
CN (1) CN101080225A (enExample)
AR (1) AR052052A1 (enExample)
AU (1) AU2005315855A1 (enExample)
BR (1) BRPI0519656A2 (enExample)
CA (1) CA2589493A1 (enExample)
EA (1) EA200701159A1 (enExample)
IL (1) IL183944A0 (enExample)
NO (1) NO20072325L (enExample)
PE (1) PE20060768A1 (enExample)
TW (1) TW200637546A (enExample)
UY (1) UY29274A1 (enExample)
WO (1) WO2006063737A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
BRPI0817822A2 (pt) * 2007-10-19 2015-03-31 Otsuka Pharma Co Ltd Preparação sólida farmacêutica do tipo matriz
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
SI2252273T1 (sl) 2008-03-19 2017-06-30 Ratiopharm Gmbh Trdni farmacevtski sestavek, ki obsega nepeptidni antagonist receptorja angiotenzina II in diuretik
AR072883A1 (es) * 2008-07-31 2010-09-29 Takeda Pharmaceutical COMPOSICIoN FARMACÉUTICA SoLIDA CON EL COMPUESTO (5-METIL-2-OXO-1,3-DIOXOL-4-IL)METIL2-ETOXI-1-{[2' -(5-OXO-4,5-DIHIDRO-1,2,4-OXADIAZOL-3-IL)BIFENIL-4-IL]METIL}-1H-BENCIMIDAZOL-7-CARBOXILATO Y UN DIURÉTICO PARA LA PROFILAXIS O TRATAMIENTO DE ENFERMEDADES DEL APARATO CIRCULATORIO.
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
EP2448575A2 (en) * 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
EP2448576A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
TR200906506A2 (tr) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
EP2952196A4 (en) * 2013-01-31 2016-08-03 Sawai Seiyaku Kk MULTILAYER TABLET WITH TELMISARTAN AND HYDROCHLOROTHIAZIDE
ES2847904T3 (es) * 2013-07-23 2021-08-04 Daiichi Sankyo Co Ltd Medicamento para la prevención o el tratamiento de la hipertensión
CN106562973A (zh) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 一种抗高血压药物复方制剂
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN108653227A (zh) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 一种替米沙坦氢氯噻嗪片及其制备方法
EP4029867A1 (en) * 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
CA2472392C (en) * 2002-01-16 2009-07-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof

Also Published As

Publication number Publication date
WO2006063737A1 (en) 2006-06-22
IL183944A0 (en) 2007-10-31
BRPI0519656A2 (pt) 2009-03-03
UY29274A1 (es) 2006-07-31
PE20060768A1 (es) 2006-09-29
KR20070097511A (ko) 2007-10-04
NO20072325L (no) 2007-07-06
EP1827424A1 (en) 2007-09-05
CA2589493A1 (en) 2006-06-22
AR052052A1 (es) 2007-02-28
CN101080225A (zh) 2007-11-28
EA200701159A1 (ru) 2007-12-28
AU2005315855A1 (en) 2006-06-22
JP2008524136A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
TW200637546A (en) Combination therapy
IL273765A (en) Combinations and forms of administration of therapeutic agents and combined treatment
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
AU2003210300A1 (en) The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
EP2248519A3 (en) Non-mucoadhesive film dosage forms
WO2004010975A3 (en) Controlled drug delivery
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
WO2005048850A3 (en) Systems and methods relating to associating a medical implant with a delivery device
WO2004087011A3 (en) Therapeutic agent delivery device with controlled therapeutic agent release rates
UA83854C2 (uk) Застосування телмісартану для підвищення чутливості до інсуліну
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
WO2004064734A3 (en) Combination therapies for the treatment of cancer
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MY137620A (en) Therapeutic treatment
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
TW200509909A (en) Use of organic compounds
WO2009134056A3 (ko) 약제학적 제제
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
WO2006030030A3 (de) System zur sequentiellen, transdermalen verabreichung von systemisch wirksamen substanzen
TH83710A (th) การบำบัดรวม
MX2009008873A (es) Composicion util para el tratamiento de diabetes tipo 2.